Pasithea Therapeutics Corp (KTTA) Stock Analysis

Verdict: HOLD

KTTA is a 'negative enterprise value' play where the market values the pipeline at less than zero; clinical data is the only unlock.

Investment score: 48/100

Analysis as of 2026-07-01

Is Pasithea Therapeutics Corp stock worth reviewing? AI model thesis

The AI model rates KTTA as a speculative BUY due to an extreme valuation anomaly where the company trades at 0.27x book value with cash reserves exceeding market cap.

7-factor investment score

Valuation: 85/100 (weight 20%)
Financial Health: 30/100 (weight 15%)
Technical Momentum: 25/100 (weight 15%)
Earnings Quality: 20/100 (weight 15%)
Insider Sentiment: 90/100 (weight 10%)
Analyst Consensus: 70/100 (weight 10%)
Risk-Adjusted Return: 40/100 (weight 15%)

Pasithea Therapeutics Corp opportunities and risks

What speaks for KTTA

Negative Enterprise Value Disconnect

What speaks against KTTA

Cash Runway and Burn Rate

Peers and competitors

Trailing-twelve-month ratios
Ticker	P/E	P/S	EV/EBITDA	Gross margin	Net margin	FCF yield
KTTA	n/a	0.0x	2.2x	0.0%	0.0%	-441.7%
GRTX	0.1x	0.0x	n/a	0.0%	0.0%	-44.8%
TPST	n/a	0.0x	n/a	0.0%	0.0%	-535.2%
AEON	n/a	0.0x	n/a	0.0%	0.0%	-141.4%
HOWL	n/a	0.0x	n/a	0.0%	0.0%	-297.0%
CELU	n/a	0.5x	n/a	76.0%	-345.4%	-92.2%
Peer median	n/a	0.0x	n/a	0.0%	0.0%	-141.4%

Frequently asked questions about Pasithea Therapeutics Corp (KTTA)

Is KTTA stock a good investment?

The cached TradeMates AI model rates Pasithea Therapeutics Corp as HOLD with an investment score of 48/100. The AI model rates KTTA as a speculative BUY due to an extreme valuation anomaly where the company trades at 0.27x book value with cash reserves exceeding market cap. This is algorithmic model output, not personal investment advice.

Is KTTA stock a buy?

The TradeMates model verdict for KTTA is HOLD with an investment score of 48/100. Treat this as a model signal to review, not a personal buy recommendation.